Rifapentine
ریفاپنتین
🦠 Antiinfectives For Systemic UseRifamycin
Market / country: 🇺🇸 USA
Priftin (US)
🧮 Dose calculator
Latent tuberculosis infection · Regimen source: FDA Priftin · 2.2, Table 1
- • Weekly isoniazid 15 mg/kg (≥12 y) or 25 mg/kg (2–11 y), max 900 mg. With meals. FDA Priftin · 2.2FDA Priftin · 2.3
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to rifamycins. FDA Priftin · 4
Warnings
- • Hepatotoxicity; hypersensitivity and severe skin reactions; TB relapse; many drug interactions (CYP3A inducer); body-fluid discoloration; porphyria. FDA Priftin · 5
Formulations
- 150 mg tablet — tablet 🇺🇸 USA FDA Priftin · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Priftin · 8.1
“Risk Summary Based on animal data, PRIFTIN may cause fetal harm when administered to a pregnant woman.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Priftin · 8.2
“Risk Summary There are no data on the presence of rifapentine or its metabolite in human or animal milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Priftin · 8.4
“The safety and effectiveness of PRIFTIN in the treatment of active pulmonary tuberculosis have not been established in pediatric patients under the age of 12.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Priftin · 8.5
“Clinical studies with PRIFTIN did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Priftin · 8.3
“Contraception Use of PRIFTIN may reduce the efficacy of hormonal contraceptives.”
🔗 Reference links
- FDA (approval record)NDA021024
- DailyMed (FDA label)FDA Priftin
- MedlinePlus (NIH)Rifapentine
- WHO ATC/DDDJ04AB05
- Darooyab (Iran)Rifapentine
🇮🇷 Registered in Iran Darooyab · G-494/Rifapentine
Dosage forms with Iranian generic codes, per Darooyab.
- 52163 · RIFAPENTINE TABLET ORAL 150 mg · قرص ریفاپنتین ۱۵۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Priftin · 3FDA Priftin · 2.2, Table 1FDA Priftin · 2.2FDA Priftin · 2.3FDA Priftin · 2.1FDA Priftin · 4FDA Priftin · 5FDA Priftin · SPL approval / marketing categoryFDA Priftin · 8.1FDA Priftin · 8.2FDA Priftin · 8.4FDA Priftin · 8.5FDA Priftin · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-494/Rifapentine
- Clinical review⚠ Unverified